Clinical course of Crohn’s disease in a population-based cohort in Uppsala County followed for 10 years

Abstract

Background and aims

There is a shortage of studies describing the outcome of patients with Crohn’s disease (CD) where both biological therapy and immunomodulators (IMMs) have been available. The aim of the present study was to describe the clinical course of the disease, the use of drugs, the need for surgery and mortality in a prospectively recruited population-based cohort of patients followed for 10 years.

Methods

All patients diagnosed with CD in the County of Uppsala in Sweden 2005–2009 were prospectively recruited and followed until the end of 2019. The medical notes were scrutinised and relevant information collected.

Results

One hundred and fifty-four patients covering all age groups were diagnosed with CD and 145 (94.2%) could be followed for 10 years or until death. Nine patients were lost to follow up. The following drugs were used: 5-ASA 83%, steroids 84%, IMMs 69% and biologicals 23%. The proportion of penetrating disease increased from 9.7 to 14.5%. Primary bowel resections were performed in 22% of the patients, and none of these had any secondary surgery because of recurrent or progressive disease during the observation time. Twelve patients (7.8%) died during the follow up, and one of these because of a small bowel carcinoma.

Conclusions

In the present study, the clinical course of CD was similar to previous reports during the first year after diagnosis, but the following years were considerably more stable with moderate increase of intestinal damage and totally a low frequency of surgery and no repeated surgery.

Keywords:

• Crohn’s disease
• epidemiology
• clinical course

Acknowledgements

Guarantor of the article: Anders Rönnblom.

Disclosure statement

The authors have no conflicts of interest to declare.

Additional information

Funding

This work was supported by grants from the Uppsala University Hospital Research Foundation.